Cgs 34043

Autor: Trapani, A. J., Lombaert, S. De, Beil, M. E., Bruseo, C. W., Savage, P., Chou, M., Jeng, A. Y.

Publikováno v: Life Sciences; 2000, Vol. 67 Issue: 9 p1025-1033, 9p

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.

Autor: Firooznia F; Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA. fariborz.firooznia@pharma.novartis.com, Gude C, Chan K, Fink CA, Qiao Y, Satoh Y, Marcopoulos N, Savage P, Beil ME, Bruseo CW, Trapani AJ, Jeng AY

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2001 Feb 12; Vol. 11 (3), pp. 375-8.

Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.

Autor: Trapani AJ; Metabolic and Cardiovascular Diseases Research, Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA., Beil ME, Bruseo CW, De Lombaert S, Jeng AY

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2000 Nov; Vol. 36 (5 Suppl 1), pp. S40-3.

Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.

Autor: Webb RL; Metabolic and Cardiovascular Diseases, Novartis Pharmaceuticals Corp, Summit, New Jersey 07901, U.S.A., Abramson ML, Beil ME, Odorico LM, Chatelain RE

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 1997 Nov; Vol. 30 (5), pp. 632-42.

Antiarrhythmic evaluation of naloxone against acute coronary occlusion-induced arrhythmias in pigs.

Autor: Bergey JL, Beil ME

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 1983 Jun 17; Vol. 90 (4), pp. 427-31.